Shay Capital’s Biogen BIIB Stock Holding History

Shay Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,000	Closed	-$1.6M	–	293
2022 Q3	$1.6M	Buy	+6,000	New	+$1.27M	0.35%	50
2022 Q1	–	Sell	-8,400	Closed	-$2.02M	–	514
2021 Q4	$2.02M	Buy	+8,400	New	+$2.16M	0.33%	53

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Shay Capital's BIIB Position: Q4 2025 in Review

Shay Capital sold out of Biogen (BIIB) in Q4 2025, closing a stake of 9,000 shares — an estimated $1.26M sold.

Shay Capital first reported a position in BIIB in Q3 2022 and held it in 4 quarters. The position peaked at $2.06M in Q3 2022. 998 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Shay Capital reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Shay Capital sold 9,000 Biogen shares in Q4 2025, an estimated $1.26M.
Shay Capital first reported a position in Biogen in Q3 2022 and held it in 4 quarters.
Shay Capital's Biogen position peaked at $2.06M in Q3 2022.
998 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Shay Capital's 13F filing for Q4 2025, filed 17 Feb 2026.